Need Assistance?
  • US & Canada:
    +
  • UK: +

Histone H2B 1

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Histone H2B 1 is an antibacterial peptide isolated from Ictalurus punctatus. It has activity against bacteria and fungi.

Category
Functional Peptides
Catalog number
BAT-012399
Molecular Formula
C85H149N25O24
Molecular Weight
2034.62
Sequence
PDPAKTAPKKGSKKAVTKXA
1. SHP-1 dephosphorylates histone H2B to facilitate its ubiquitination during transcription
Prajakta Tathe, K V S Rammohan Chowdary, Krushna Chandra Murmu, Punit Prasad, Subbareddy Maddika EMBO J. 2022 Oct 4;41(19):e109720. doi: 10.15252/embj.2021109720. Epub 2022 Aug 8.
Dynamic regulation of phosphorylation and dephosphorylation of histones is essential for eukaryotic transcription, but the enzymes engaged in histone dephosphorylation are not fully explored. Here, we show that the tyrosine phosphatase SHP-1 dephosphorylates histone H2B and plays a critical role during transition from the initiation to the elongation stage of transcription. Nuclear-localized SHP-1 is associated with the Paf1 complex at chromatin and dephosphorylates H2B at tyrosine 121. Moreover, knockout of SHP-1, or expression of a mutant mimicking constitutive phosphorylation of H2B Y121, leads to a reduction in genome-wide H2B ubiquitination, which subsequently causes defects in RNA polymerase II-dependent transcription. Mechanistically, we demonstrate that Y121 phosphorylation precludes H2B's interaction with the E2 enzyme, indicating that SHP-1-mediated dephosphorylation of this residue may be a prerequisite for efficient H2B ubiquitination. Functionally, we find that SHP-1-mediated H2B dephosphorylation contributes to maintaining basal autophagic flux in cells through the efficient transcription of autophagy and lysosomal genes. Collectively, our study reveals an important modification of histone H2B regulated by SHP-1 that has a role during eukaryotic transcription.
2. Phase separation directs ubiquitination of gene-body nucleosomes
Laura D Gallego, Maren Schneider, Chitvan Mittal, Anete Romanauska, Ricardo M Gudino Carrillo, Tobias Schubert, B Franklin Pugh, Alwin Köhler Nature. 2020 Mar;579(7800):592-597. doi: 10.1038/s41586-020-2097-z. Epub 2020 Mar 11.
The conserved yeast E3 ubiquitin ligase Bre1 and its partner, the E2 ubiquitin-conjugating enzyme Rad6, monoubiquitinate histone H2B across gene bodies during the transcription cycle1. Although processive ubiquitination might-in principle-arise from Bre1 and Rad6 travelling with RNA polymerase II2, the mechanism of H2B ubiquitination across genic nucleosomes remains unclear. Here we implicate liquid-liquid phase separation3 as the underlying mechanism. Biochemical reconstitution shows that Bre1 binds the scaffold protein Lge1, which possesses an intrinsically disordered region that phase-separates via multivalent interactions. The resulting condensates comprise a core of Lge1 encapsulated by an outer catalytic shell of Bre1. This layered liquid recruits Rad6 and the nucleosomal substrate, which accelerates the ubiquitination of H2B. In vivo, the condensate-forming region of Lge1 is required to ubiquitinate H2B in gene bodies beyond the +1 nucleosome. Our data suggest that layered condensates of histone-modifying enzymes generate chromatin-associated 'reaction chambers', with augmented catalytic activity along gene bodies. Equivalent processes may occur in human cells, and cause neurological disease when impaired.
3. The expanding landscape of 'oncohistone' mutations in human cancers
Benjamin A Nacev, et al. Nature. 2019 Mar;567(7749):473-478. doi: 10.1038/s41586-019-1038-1. Epub 2019 Mar 20.
Mutations in epigenetic pathways are common oncogenic drivers. Histones, the fundamental substrates for chromatin-modifying and remodelling enzymes, are mutated in tumours including gliomas, sarcomas, head and neck cancers, and carcinosarcomas. Classical 'oncohistone' mutations occur in the N-terminal tail of histone H3 and affect the function of polycomb repressor complexes 1 and 2 (PRC1 and PRC2). However, the prevalence and function of histone mutations in other tumour contexts is unknown. Here we show that somatic histone mutations occur in approximately 4% (at a conservative estimate) of diverse tumour types and in crucial regions of histone proteins. Mutations occur in all four core histones, in both the N-terminal tails and globular histone fold domains, and at or near residues that contain important post-translational modifications. Many globular domain mutations are homologous to yeast mutants that abrogate the need for SWI/SNF function, occur in the key regulatory 'acidic patch' of histones H2A and H2B, or are predicted to disrupt the H2B-H4 interface. The histone mutation dataset and the hypotheses presented here on the effect of the mutations on important chromatin functions should serve as a resource and starting point for the chromatin and cancer biology fields in exploring an expanding role of histone mutations in cancer.
Online Inquiry
Verification code
Inquiry Basket